ClinicalTrials.gg

Program

Sirolimus

Also written as “sirolimus”, “Rapamycin” and “Sirolimus for Injection (Albumin-bound)”.

Its studies are mostly in Renal Insufficiency · Kidney Failure, Chronic · Breast Neoplasms · Tuberous Sclerosis · Uveitis, led by 18 companies.

Furthest: phase 4, since Sep 4, 200265 company-led studies, 15 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer260 open or runningphase 4since Sep 4, 2002May 17, 2002none ahead
CSPC Pharmaceutical Group85 open or runningphase 3since Apr 8, 2025Oct 25, 2021Oct 2027phase 1 · NCT06941142
Santen Pharmaceutical70 open or runningphase 3since May 19, 2011Nov 15, 2006none ahead
Astellas Pharma31 open or runningphase 4since May 31, 2011May 31, 2011Oct 31, 2027phase 2 · NCT07052929
Umoja Biopharma33 open or runningphase 2since Jul 24, 2026Jul 25, 2024Mar 2029phase 1 · NCT06528301
AgelessRx21 open or runningphase 3since Dec 18, 2024Jul 13, 2020none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Nov 18, 2014Nov 18, 2014none ahead
Hoffmann-La Roche20 open or runningphase 4since Jul 15, 2005Jul 15, 2005none ahead
Nobelpharma20 open or runningphase 1since Dec 3, 2018Dec 3, 2018none ahead
Vascular Therapies20 open or runningphase 3since Jul 29, 2015Jul 29, 2015none ahead
aft-pharmaceuticals-ltd11 open or runningphase 2since Feb 22, 2026Feb 22, 2026Oct 2027phase 2 · NCT07436611
aucta-pharmaceuticals-inc10 open or runningphase 2since Dec 1, 2017Dec 1, 2017none ahead
Chong Kun Dang Pharmaceutical11 open or runningphase 4since Jan 3, 2022Jan 3, 2022none ahead
concept-medical-inc11 open or runningphase 3since Jan 21, 2026Jan 21, 2026Dec 2027phase 3 · NCT07359807
dermatology-specialties-limited-partnership10 open or runningphase 3since Jan 29, 2019Jan 29, 2019none ahead
Eli Lilly11 open or runningphase 2since May 11, 2020May 11, 2020Feb 2027phase 2 · NCT04411654
nanjing-iaso-biotechnology-co-ltd11 open or runningphase 1since Dec 10, 2024Dec 10, 2024May 21, 2028phase 1 · NCT06743503
transderm-inc10 open or runningphase 1since Feb 5, 2014Feb 5, 2014none ahead
  • Named in CSPC Pharmaceutical Group’s own pipeline as sirolimus for injection (albumin-bound), phase 4, as of Aug 20, 2026 (source).

Also a collaborator on its studies: basilea-pharmaceutica-international-ltd and macusight-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Aug 1, 2005.

  1. Nov 14, 2022Phase 2 study in Perivascular Epithelioid Cell NeoplasmsCSPC Pharmaceutical Group · NCT05625919 · 54 enrolled · China
  2. Jul 25, 2024Umoja Biopharma's first study: phase 1 study in Lymphoma, B-CellNew to Umoja BiopharmaUmoja Biopharma · NCT06528301 · 106 planned · United States, Australia
  3. Dec 10, 2024nanjing-iaso-biotechnology-co-ltd's first study: phase 1 study in RecurrenceNew to nanjing-iaso-biotechnology-co-ltdnanjing-iaso-biotechnology-co-ltd · NCT06743503 · 70 planned · China
  4. Dec 18, 2024Phase 3 study in LongevityAgelessRx · NCT07092618 · 150 planned · United States
  5. Apr 8, 2025Phase 3 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT06929325 · 312 planned · China
  6. Apr 16, 2025Phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142 · 382 planned
  7. Apr 26, 2025Phase 2 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT06957379 · 78 enrolled · China
  8. Jun 30, 2025Phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929 · 9 planned · United States, Canada
  9. Sep 3, 2025Phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsCSPC Pharmaceutical Group · NCT07165886 · 298 planned · China
  10. Jan 21, 2026concept-medical-inc's first study: phase 3 study in Peripheral Arterial DiseaseNew to concept-medical-incconcept-medical-inc · NCT07359807 · 478 planned
  11. Feb 22, 2026aft-pharmaceuticals-ltd's first study: phase 2 study in Hemangioma, CapillaryNew to aft-pharmaceuticals-ltdaft-pharmaceuticals-ltd · NCT07436611 · 30 planned · United States, Spain
  12. Jun 29, 2026Phase 2 study in Hemangioendothelioma, EpithelioidCSPC Pharmaceutical Group · NCT07684287 · 40 planned · China
  13. Jul 24, 2026Phase 1 study in Multiple MyelomaUmoja Biopharma · NCT07735546 · 100 planned · Australia
  14. Jul 24, 2026Phase 2 study in Lymphoma, B-CellPhase 2 reachedUmoja Biopharma · NCT07735533 · 274 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 2 study in Gaucher DiseaseEli Lilly · NCT04411654
  2. Oct 2027Primary completion: phase 2 study in Hemangioma, Capillaryaft-pharmaceuticals-ltd · NCT07436611
  3. Oct 2027Primary completion: phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142
  4. Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929

TargetBeta

“A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian …”NCIt, read by Claude
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule

Other programs on MTOR

ProgramCompanyFurthest phaseStudies
gedatolisibrulePfizerphase 39
PI3K/mTOR Kinase Inhibitor WXFL10030390ruleshanghai-jiatan-pharmatech-co-ltdphase 36
sapanisertibruleTakedaphase 214

Studies

The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07735546Multiple Myeloma · Australia1RecruitingUmoja BiopharmaDec 31, 2029100
NCT07735533Lymphoma, B-Cell · United States2RecruitingUmoja BiopharmaAug 2031274
NCT07684287Hemangioendothelioma, Epithelioid · China2Not yet recruitingCSPC Pharmaceutical GroupNov 30, 202740
NCT07436611Hemangioma, Capillary · United States, Spain2Not yet recruitingaft-pharmaceuticals-ltdOct 202730
NCT07359807Peripheral Arterial Disease3Not yet recruitingconcept-medical-incDec 2027478
NCT07165886Gastroenteropancreatic Neuroendocrine Tumors · China3RecruitingCSPC Pharmaceutical GroupAug 29, 2028298
NCT07052929Myopathies, Structural, Congenital · United States, Canada2RecruitingAstellas PharmaOct 31, 20279
NCT06957379Breast Neoplasms · China2Active, not recruitingCSPC Pharmaceutical GroupJun 202578
NCT06941142Advanced Breast Cancer1Not yet recruitingCSPC Pharmaceutical GroupOct 2027382
NCT06929325Breast Neoplasms · China3Not yet recruitingCSPC Pharmaceutical GroupOct 2026312
NCT07092618Longevity · United States3RecruitingAgelessRxAug 2025150
NCT06743503Recurrence · China1Recruitingnanjing-iaso-biotechnology-co-ltdMay 21, 202870
NCT06528301Lymphoma, B-Cell · United States, Australia1RecruitingUmoja BiopharmaMar 2029106
NCT05625919Perivascular Epithelioid Cell Neoplasms · China2UNKNOWNCSPC Pharmaceutical GroupNov 202454
NCT05508620Malignant Solid Tumors1UNKNOWNCSPC Pharmaceutical GroupDec 2024270
NCT05425056Kidney Failure, Chronic · United States, United Kingdom3CompletedVascular TherapiesMar 18, 2025136
NCT05193565Kidney Transplantation · South Korea4Active, not recruitingChong Kun Dang PharmaceuticalJul 2026206
NCT05125523Advanced Solid Tumors · China1UNKNOWNCSPC Pharmaceutical GroupJun 2024264
NCT04488601Aging · United States2CompletedAgelessRxDec 30, 2023129
NCT04411654Gaucher Disease · United States, United Kingdom2Active, not recruitingEli LillyFeb 20277
NCT03972462Bioavailability Study · United States1CompletedNobelpharmaJun 17, 201912
NCT03826628Tuberous Sclerosis · United States, Australia, Czechia and more3Completeddermatology-specialties-limited-partnershipSep 1, 2022107
NCT03765944Bioequivalence Study · Japan1CompletedNobelpharmaDec 29, 201810
NCT03363763Tuberous Sclerosis · United States, China2Terminatedaucta-pharmaceuticals-incMar 24, 202324
NCT02686619Renal Transplantation · France3CompletedHoffmann-La RocheJan 2011237
NCT02513303Kidney Failure, Chronic · United States3CompletedVascular TherapiesJun 2021269
NCT02296762Healthy · India1CompletedDr. Reddy's LaboratoriesFeb 201036
NCT02296749Healthy · India1CompletedDr. Reddy's LaboratoriesJan 201060
NCT02251938Non-Infectious Uveitis of the Posterior Segment of the Eye · United States, Austria, France and more3CompletedSanten PharmaceuticalNov 1, 201760
NCT02152007Pachyonychia Congenita · United States1Completedtransderm-incJul 201515
NCT01809860Healthy Subjects · United States1CompletedAstellas PharmaJan 201222
NCT01363752Acute Kidney Injury · Australia, Austria, Belarus and more4CompletedAstellas PharmaSep 18, 2013853
NCT01358266Uveitis · United States, Argentina, Austria and more3CompletedSanten PharmaceuticalSep 2016592
NCT01236378Transplant Rejection · China1CompletedPfizerApr 201124
NCT00895583Graft Rejection · United States, Argentina, Australia and more4CompletedPfizerAug 2013254
NCT00814944Dry Eye Syndromes · United States2CompletedSanten PharmaceuticalOct 2009143
NCT00766337Macular Degeneration · United States2TerminatedSanten PharmaceuticalNov 200962
NCT00712491Macular Degeneration · United States2TerminatedSanten PharmaceuticalNov 200920
NCT00656643Diabetic Macular Edema · United States2CompletedSanten PharmaceuticalNov 2009131
NCT00519116Kidney Transplantation4CompletedPfizer150
NCT00518375Kidney Transplantation4CompletedPfizer250
NCT00518271Kidney Transplantation2CompletedPfizer120
NCT00507793Kidney Transplantation4CompletedPfizer385
NCT00478608Renal Transplant · Korea, Republic of3CompletedPfizerNov 200879
NCT00470665Renal Allograft Recipients3CompletedPfizer460
NCT00452361Kidney Transplantation · Taiwan4TerminatedPfizerAug 200831
NCT00428064Renal Transplantation3CompletedPfizer408
NCT00401115Diabetic Retinopathy · United States1CompletedSanten PharmaceuticalJun 200850
NCT00369382Renal Insufficiency · United States, Australia, Austria and more4CompletedPfizerApr 2010121
NCT00311311Atherosclerosis · United States, Canada3TerminatedPfizerDec 201072
NCT00282217Renal Insufficiency · Spain4CompletedPfizer100
NCT00266123Renal Insufficiency4CompletedPfizer420
NCT00261820Renal Insufficiency4CompletedPfizer160
NCT00254709Renal Insufficiency4CompletedPfizer66
NCT00248313Kidney Diseases3CompletedPfizer470
NCT00195481Renal Insufficiency · India4CompletedPfizerDec 2005100
NCT00195273Graft vs Host Disease · Norway, Sweden3CompletedPfizerJul 200861
NCT00167947Renal Insufficiency · Italy3CompletedPfizerJul 2007150
NCT00137345Kidney Transplant · United States, Argentina, Australia and more3TerminatedPfizerAug 2006500
NCT00129961Skin Neoplasms · United States, Australia, Canada and more4CompletedPfizerJan 200986

How it is read

Names in the registry

  • “Sirolimus”, 28 entries
  • “sirolimus”, 8 entries
  • “Rapamycin”, 3 entries
  • “Sirolimus for Injection (Albumin-bound)”, 3 entries
  • “Rapamune® (Sirolimus)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.